• Revenue and volume growth: Metropolis recorded 17% revenue growth driven by 10% volume growth and 7% realization growth, without any price hikes. The company expects to maintain a 9% to 10% patient volume growth rate for the remainder of the year.
• Pricing strategy: The company has not raised prices for 18 months, passing on cost benefits derived from GST to consumers, and does not plan any price increases for the next two quarters.
• Margin expansion targets: Management expects full-year EBITDA margins to expand by 125 to 150 basis points over the prior year's 24.4% to reach around 26%, targeting 27% to 28% within two years.
• Geographic and tier expansion: Tier 3 markets grew 25% year-on-year due to maturing network additions, while North India's revenue contribution rose from 5% to 18% over the past 2 to 2.5 years, posting 19% growth in the quarter.
• M&A pipeline: Supported by a low-leverage balance sheet and healthy cash flows, the company is conducting due diligence on targets in its funnel and remains actively focused on inorganic acquisitions.